CANbridge (北海康成) Pre-IPO: Not the Cup of Tea for Secondary Market
CANbridge is seeking a USD 200m listing in Hong Kong. We look at CANbridge's commercialized products (Caphosol, Nerlynx, Hunterase) and the core...
171 Views
Hong Kong Connect Flows: Chinese Buying Tencent Before Results
We highlight inflows into Tencent (700 HK), Pop Mart (9992 HK), Kuaishou (1024 HK), as well as outflows from Wuxi Biologics (Cayman) Inc. (2269 HK).
120 Views
Wuxi Biologics (2269.HK) 2021Q3 - The Strength and the Concerns Behind the New Full-Year Guidance
This insight mainly analyzed WuXi Biologics in terms of the new full-year guidance, CMO business, profit quality, other moats, and the concerns of...
238 Views
MicroPort MedBot IPO Trading - Decent Demand But Upside Is Limited from the Top-End
Shanghai MicroPort MedBot Group (MM), a surgical robot company, raised around US$200m in its Hong Kong IPO. In this note we will talk about the...
176 Views
Pharmaron Beijing Co Ltd (3759.HK) 2021Q3 - Still Takes Time to Challenge Wuxi AppTec
The insight analyzed Pharmaron from a different angle after it released the 2021Q3 results,which included the key bottleneck and concerns in terms...
174 Views